Practical guidance for prescribing with aripiprazole in bipolar disorder

References

• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 2001;62:841–21Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 2001;62:841–2
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company/Otsuka Pharmaceutical Europe Ltd, Abilify (aripiprazole) Summary of Product Characteristics. 2006, Bristol-Myers Squibb Company/Otsuka Pharmaceutical Europe Ltd2Bristol-Myers Squibb Company/Otsuka Pharmaceutical Europe Ltd, Abilify (aripiprazole) Summary of Product Characteristics. 2006, Bristol-Myers Squibb Company/Otsuka Pharmaceutical Europe Ltd
   Google Scholar
• Abilify. Bristol-Myers Squibb/Otsuka America Pharmaceutical Inc, Aripiprazole (Abilify) Prescribing Information. Bristol-Myers Squibb & Otsuka America Pharmaceutical, Inc: Princeton, NJ. 2007.3Abilify. Bristol-Myers Squibb/Otsuka America Pharmaceutical Inc, Aripiprazole (Abilify) Prescribing Information. Bristol-Myers Squibb & Otsuka America Pharmaceutical, Inc: Princeton, NJ. 2007.
   Google Scholar
• Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: a 12-week, randomized placebo- and haloperidol-controlled study. Br J Psychiatry. in press4Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: a 12-week, randomized placebo- and haloperidol-controlled study. Br J Psychiatry. in press
   Web of Science ®Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S. et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–85Keck PE Jr, Marcus R, Tourkodimitris S. et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651–8
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R. et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536–466Sachs G, Sanchez R, Marcus R. et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536–46
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R. et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235–427Vieta E, Bourin M, Sanchez R. et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235–42
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. Journal of Affective Disorders. in press8Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. Journal of Affective Disorders. in press
   Google Scholar
• Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry doi: 10.1176/appi.ajp.2008.071015609Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry doi: 10.1176/appi.ajp.2008.07101560
   Google Scholar
• Keck PE, Calabrese J, McQuade RD. et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–3710Keck PE, Calabrese J, McQuade RD. et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626–37
   PubMed Web of Science ®Google Scholar
• Keck PE Jr., Calabrese JR, McIntyre RS. et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480–9111Keck PE Jr., Calabrese JR, McIntyre RS. et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480–91
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Marcus RN, Manos G. et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27:171–612Zimbroff DL, Marcus RN, Manos G. et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27:171–6
   PubMed Web of Science ®Google Scholar
• Andrezina R, Josiassen R, Marcus R. et al. Intramuscular aripiprazole or haloperidol for the treatment of acute agitation associated with schizophrenia: sub-analysis of a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:2209–1913Andrezina R, Josiassen R, Marcus R. et al. Intramuscular aripiprazole or haloperidol for the treatment of acute agitation associated with schizophrenia: sub-analysis of a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:2209–19
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398–40514Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398–405
   PubMed Web of Science ®Google Scholar
• Ciraulo DA, Nace EP. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 2000; 9:276–915Ciraulo DA, Nace EP. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 2000; 9:276–9
   PubMed Web of Science ®Google Scholar
• Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series. Treatment of Behavioral Emergencies. A Postgraduate Medicine Special Report. 2001.16Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series. Treatment of Behavioral Emergencies. A Postgraduate Medicine Special Report. 2001.
   Google Scholar
• Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207–2217Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207–22
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12–2118Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12–21
   PubMed Web of Science ®Google Scholar
• Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005;20:179–8119Pfeffer G, Chouinard G, Margolese HC. Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. Int Clin Psychopharmacol 2005;20:179–81
   PubMed Web of Science ®Google Scholar
• Spurling RD, Lamberti JS, Olsen D. et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406–920Spurling RD, Lamberti JS, Olsen D. et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406–9
   PubMed Web of Science ®Google Scholar
• Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68:5–921Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007;68:5–9
   PubMed Web of Science ®Google Scholar
• Taylor D, Atkinson J, Fischetti C. et al. A prospective 6-month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome. Acta Psychiatr Scand 2007;116:461–622Taylor D, Atkinson J, Fischetti C. et al. A prospective 6-month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome. Acta Psychiatr Scand 2007;116:461–6
   PubMed Web of Science ®Google Scholar
• Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006;67:160–123Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006;67:160–1
   PubMed Web of Science ®Google Scholar